Lenvatinib/Pembrolizumab Upholds Efficacy Vs Sunitinib in Frontline Advanced RCC Vs Sunitinib
November 6th 2022After approximately 33 months of extended follow-up in the CLEAR study, investigators say lenvatinib plus pembrolizumab should be considered a standard of care option for frontline advanced renal cell carcinoma.
Read More
Need for Subsequent Therapy Limited With Lenvatinib/Pembrolizumab in Advanced RCC
November 5th 2022Subsequent therapy rates were lower in patients with advanced renal cell carcinoma treated with the combination of lenvatinib and pembrolizumab vs those who received sunitinib in the CLEAR trial.
Read More
Nivolumab Plus Ipilimumab Prolongs Survival in Treatment-Naïve Advanced Sarcomatoid RCC
November 5th 2022Post hoc CheckMate 214 results show that nivolumab plus ipilimumab extend progression and overall survival in patient with advanced sarcomatoid renal cell carcinoma who have not be previously treated.
Read More
Doctors Debate: Should Upfront Therapy for RCC Consist of Doublets or Triplets?
November 4th 2022During a debate at the 2022 International Kidney Cancer Symposium, Yousef Zakharia, MD and Rana M. McKay, MD presented argument for the use of doublets or triplets in patients with renal cell carcinoma.canc
Read More
Case of Twins with Rare Stem Cell Disorder Wins Best Overall Abstract at Congress on MPNs
October 28th 2022At the 14th International Congress on Myeloproliferative Neoplasms, research into the case of dizygotic twins with essential thrombocythemia won the Best overall Abstract Award for concluding how their rare stem cell disorder was passed between both twins.
Read More
Wearable Patient-Tracking Device to Inform Time and Delivery of Radiotherapy
October 22nd 2022Alonso Gutierrez, MD, discusses the initial results from a feasibility study which evaluated the use of a daily wearable patient-tracking device to optimize radiation machine use and time the delivery of treatment.
Watch
Psychiatric History May Prompt Patients’ Decisions for Faster Surgical Treatment in Thyroid Cancer
October 22nd 2022Psychiatric history may be an important factor for physicians to consider when counseling patients on their treatment options with thyroid cancer, according to a retrospective chart review.
Read More
Cancer Survivors May Be at Increased Risk for Secondary Primary Thyroid Cancer
October 21st 2022A study found that after their first primary malignancy diagnosis, cancer survivors are at a significantly increased risk for secondary primary thyroid cancer, with other half of cases occurring in the first 3 years.
Read More
Withholding RAI Therapy in Low-Risk Pediatric DTC Continues to Yield Comparable Remission Rates
October 20th 2022Following American Thyroid Association guidelines, a retrospective study confirmed that remission rates were comparable in pediatric patients with low-risk differentiated thyroid carcinoma who did and did not receive radioactive iodine therapy.
Read More
Addition of Atezolizumab to Vemurafenib/Cobimetinib May Improve Survival in BRAF V600E-Mutated ATC
October 20th 2022The combination use of a BRAF/MEK inhibitor plus checkpoint inhibitor immunotherapy did not meet median overall survival at 2 years, hinting at the combinations’ improved efficacy in patients with BRAF V600E-mutated anaplastic thyroid cancer.
Read More
Assessing Risk for Optimal Treatment of High-Risk Polycythemia Vera in the Frontline Setting
October 18th 2022During the NCCN 2022 Annual Congress: Hematologic Malignancies, Aaron Gerds, MD, explained risk stratification in patients with polycythemia vera, frontline treatment options, and outcomes for the patient population based on findings from clinical trials.
Read More
Evaluating Effective Treatment Options and Strategies for Relapsed/Refractory Mantle Cell Lymphoma
October 15th 2022At the 2022 NCCN annual congress, Tycel Phillips, MD, discussed different strategies that can be effective as second-line treatments in various patients who have relapsed/refractory mantle cell lymphoma.
Read More
Utilizing Immunotherapy Treatments and Managing Toxicities in Multiple Myeloma
October 15th 2022At a 2022 NCCN meeting, a panel discussed the use of immunotherapy for the treatment of patients with multiple myeloma, specifically how to choose the best course of action and how to manage toxicities.
Read More